Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Medicenna Therapeutics Corp. has reported promising results from its Phase 1/2 ABILITY-1 study, showcasing significant single-agent activity of MDNA11 in patients with advanced solid tumors. The study also highlights a favorable safety profile when MDNA11 is combined with KEYTRUDA, indicating potential for enhanced cancer treatment options. These developments are promising for investors watching the biotech sector.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
